Welcome to our dedicated page for Eloxx Pharmaceut news (Ticker: ELOX), a resource for investors and traders seeking the latest updates and insights on Eloxx Pharmaceut stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Eloxx Pharmaceut's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Eloxx Pharmaceut's position in the market.
Eloxx Pharmaceuticals (NASDAQ: ELOX) announced the publication of a scientific manuscript on ELX-02 in the Journal of Pharmacology and Experimental Therapeutics. The study highlights ELX-02's ability to mediate read-through of premature stop codons while preserving the integrity of native stop codons. This indicates a favorable tolerability profile, as demonstrated in preclinical and clinical datasets. ELX-02 is currently undergoing Phase 2 clinical trials for cystic fibrosis patients with nonsense mutations, a crucial area with limited treatment options.
Eloxx Pharmaceuticals (NASDAQ: ELOX) announced the resumption of enrollment in its Phase 2 clinical trial for ELX-02, aimed at treating cystic fibrosis, in Israel and Europe after a COVID-19-related pause. The U.S. trial remains on hold, prioritizing health and safety. CEO Dr. Gregory Williams expressed commitment to completing enrollment and reporting top-line data promptly. ELX-02 targets rare diseases caused by nonsense mutations, a significant advancement in treating cystic fibrosis and other genetic disorders.
Eloxx Pharmaceuticals (NASDAQ: ELOX) provided a business update and financial results for Q1 2020. The company is committed to completing its Phase 2 clinical trial for ELX-02 in cystic fibrosis, although enrollment is paused due to COVID-19. As of March 31, 2020, Eloxx had $44 million in cash, sufficient to fund operations through 2021. The company reported a net loss of $13.9 million for the quarter, including $4.0 million in restructuring charges. Preclinical studies on autosomal dominant polycystic kidney disease and inherited retinal disorders are progressing.